Clinical Trial Update: Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease [Phase 2]

View source ↗

Summary

Phase 2 study of epratuzumab in serologically positive active systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Epratuzumab (epratuzumab)

Snippet

Sponsor: UCB Pharma | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED